Literature DB >> 26282381

3D tumor tissue analogs and their orthotopic implants for understanding tumor-targeting of microenvironment-responsive nanosized chemotherapy and radiation.

Pallavi Sethi1, Amar Jyoti1, Elden P Swindell2, Ryan Chan1, Ulrich W Langner3, Jonathan M Feddock3, Radhakrishnan Nagarajan4, Thomas V O'Halloran2, Meenakshi Upreti5.   

Abstract

An appropriate representation of the tumor microenvironment in tumor models can have a pronounced impact on directing combinatorial treatment strategies and cancer nanotherapeutics. The present study develops a novel 3D co-culture spheroid model (3D TNBC) incorporating tumor cells, endothelial cells and fibroblasts as color-coded murine tumor tissue analogs (TTA) to better represent the tumor milieu of triple negative breast cancer in vitro. Implantation of TTA orthotopically in nude mice, resulted in enhanced growth and aggressive metastasis to ectopic sites. Subsequently, the utility of the model is demonstrated for preferential targeting of irradiated tumor endothelial cells via radiation-induced stromal enrichment of galectin-1 using anginex conjugated nanoparticles (nanobins) carrying arsenic trioxide and cisplatin. Demonstration of a multimodal nanotherapeutic system and inclusion of the biological response to radiation using an in vitro/in vivo tumor model incorporating characteristics of tumor microenvironment presents an advance in preclinical evaluation of existing and novel cancer nanotherapies. FROM THE CLINICAL EDITOR: Existing in-vivo tumor models are established by implanting tumor cells into nude mice. Here, the authors described their approach 3D spheres containing tumor cells, enodothelial cells and fibroblasts. This would mimic tumor micro-environment more realistically. This interesting 3D model should reflect more accurately tumor response to various drugs and would enable the design of new treatment modalities.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3 dimensional triple negative breast cancer (3D TNBC) model; 3D co-cultures; Galectin-1; Targeted nanoparticle; Tumor cell spheroids; Tumor microenvironment; Tumor tissue analogs (TTA)

Mesh:

Substances:

Year:  2015        PMID: 26282381      PMCID: PMC4548830          DOI: 10.1016/j.nano.2015.07.013

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  54 in total

1.  Role of the p38 MAPK pathway in cisplatin-based therapy.

Authors:  Javier Hernández Losa; Carlos Parada Cobo; Juan Guinea Viniegra; Victor Javier Sánchez-Arevalo Lobo; Santiago Ramón y Cajal; Ricardo Sánchez-Prieto
Journal:  Oncogene       Date:  2003-06-26       Impact factor: 9.867

2.  Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response.

Authors:  Peiwen Kuo; Scott V Bratman; David B Shultz; Rie von Eyben; Cato Chan; Ziwei Wang; Carmen Say; Aparna Gupta; Bill W Loo; Amato J Giaccia; Albert C Koong; Maximilian Diehn; Quynh-Thu Le
Journal:  Clin Cancer Res       Date:  2014-09-04       Impact factor: 12.531

3.  Tumor-Endothelial Cell Three-dimensional Spheroids: New Aspects to Enhance Radiation and Drug Therapeutics.

Authors:  Meenakshi Upreti; Azemat Jamshidi-Parsian; Nathan A Koonce; Jessica S Webber; Sunil K Sharma; Alexzander Aa Asea; Mathew J Mader; Robert J Griffin
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

4.  Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.

Authors:  Hongxun Sang; Vladimir M Pisarev; Jennifer Chavez; Simon Robinson; Yajun Guo; Lori Hatcher; Corey Munger; Cathy B Talmadge; Joyce C Solheim; Rakesh K Singh; James E Talmadge
Journal:  Cancer Gene Ther       Date:  2005-04       Impact factor: 5.987

5.  A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.

Authors:  Richard W Ahn; Feng Chen; Haimei Chen; Stephan T Stern; Jeffrey D Clogston; Anil K Patri; Meera R Raja; Elden P Swindell; Vamsi Parimi; Vincent L Cryns; Thomas V O'Halloran
Journal:  Clin Cancer Res       Date:  2010-06-02       Impact factor: 12.531

Review 6.  Galectin-1: a small protein with major functions.

Authors:  Isabelle Camby; Marie Le Mercier; Florence Lefranc; Robert Kiss
Journal:  Glycobiology       Date:  2006-07-13       Impact factor: 4.313

7.  CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Authors:  Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-26       Impact factor: 11.205

Review 8.  Galectins in the tumor endothelium: opportunities for combined cancer therapy.

Authors:  Victor L J L Thijssen; Françoise Poirier; Linda G Baum; Arjan W Griffioen
Journal:  Blood       Date:  2007-06-25       Impact factor: 22.113

9.  Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment.

Authors:  Haimei Chen; Samuel Pazicni; Nancy L Krett; Richard W Ahn; James E Penner-Hahn; Steven T Rosen; Thomas V O'Halloran
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

10.  Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines.

Authors:  J Watanabe; H Nishiyama; Y Matsui; M Ito; H Kawanishi; T Kamoto; O Ogawa
Journal:  Oncogene       Date:  2006-04-20       Impact factor: 9.867

View more
  8 in total

Review 1.  Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues.

Authors:  Aleksandra Karolak; Dmitry A Markov; Lisa J McCawley; Katarzyna A Rejniak
Journal:  J R Soc Interface       Date:  2018-01       Impact factor: 4.118

2.  Toxicity evaluation of magnetic hyperthermia induced by remote actuation of magnetic nanoparticles in 3D micrometastasic tumor tissue analogs for triple negative breast cancer.

Authors:  Nathanael A Stocke; Pallavi Sethi; Amar Jyoti; Ryan Chan; Susanne M Arnold; J Zach Hilt; Meenakshi Upreti
Journal:  Biomaterials       Date:  2016-12-23       Impact factor: 12.479

3.  Heterotypic breast cancer model based on a silk fibroin scaffold to study the tumor microenvironment.

Authors:  Ewelina Dondajewska; Wojciech Juzwa; Andrzej Mackiewicz; Hanna Dams-Kozlowska
Journal:  Oncotarget       Date:  2017-12-22

4.  Cyclic hexapeptide-conjugated nanoparticles enhance curcumin delivery to glioma tumor cells and tissue.

Authors:  Xuemei Zhang; Xuejuan Li; Hongchen Hua; Aiping Wang; Wanhui Liu; Youxin Li; Fenghua Fu; Yanan Shi; Kaoxiang Sun
Journal:  Int J Nanomedicine       Date:  2017-08-08

5.  Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12.

Authors:  Brile Chung; Ali A Esmaeili; Sailesh Gopalakrishna-Pillai; John P Murad; Emily S Andersen; Naveen Kumar Reddy; Gayathri Srinivasan; Brian Armstrong; Caleb Chu; Young Kim; Tommy Tong; James Waisman; John H Yim; Behnam Badie; Peter P Lee
Journal:  NPJ Breast Cancer       Date:  2017-03-02

Review 6.  Strategies on Nanodiagnostics and Nanotherapies of the Three Common Cancers.

Authors:  Fan Leng; Fang Liu; Yongtao Yang; Yu Wu; Weiqun Tian
Journal:  Nanomaterials (Basel)       Date:  2018-03-28       Impact factor: 5.076

7.  Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer.

Authors:  Meenakshi Upreti; Amar Jyoti; Sara E Johnson; Elden P Swindell; Dana Napier; Pallavi Sethi; Ryan Chan; Jonathan M Feddock; Heidi L Weiss; Thomas V O'Halloran; B Mark Evers
Journal:  Oncotarget       Date:  2016-07-05

8.  A recapitulative three-dimensional model of breast carcinoma requires perfusion for multi-week growth.

Authors:  Kayla F Goliwas; Lauren E Marshall; Evette L Ransaw; Joel L Berry; Andra R Frost
Journal:  J Tissue Eng       Date:  2016-07-29       Impact factor: 7.813

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.